Journal Article Review Epublish 3 citations
PubMed: 38256318 DOI: 10.3390/medicina60010058
Unmasking a Silent Threat: Improving Pulmonary Hypertension Screening Methods for Interstitial Lung Disease Patients.
Medicina (Kaunas) 60(1)
Authors: Vaida Averjanovaitė, Lina Gumbienė, Ingrida Zeleckienė, Virginija Šileikienė
Affiliations
- Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania.
- Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, LT-03101 Vilnius, Lithuania.
- Clinic of Chest Diseases, Immunology and Allergology, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, LT-03101 Vilnius, Lithuania.
Abstract
This article provides a comprehensive overview of the latest literature on the diagnostics and treatment of pulmonary hypertension (PH) associated with interstitial lung disease (ILD). Heightened suspicion for PH arises when the advancement of dyspnoea in ILD patients diverges from the expected pattern of decline in pulmonary function parameters. The complexity of PH associated with ILD (PH-ILD) diagnostics is emphasized by the limitations of transthoracic echocardiography in the ILD population, necessitating the exploration of alternative diagnostic approaches. Cardiac magnetic resonance imaging (MRI) emerges as a promising tool, offering insights into hemodynamic parameters and providing valuable prognostic information. The potential of biomarkers, alongside pulmonary function and cardiopulmonary exercise tests, is explored for enhanced diagnostic and prognostic precision. While specific treatments for PH-ILD remain limited, recent studies on inhaled treprostinil provide new hope for improved patient outcomes.
MeSH
Lung Diseases, Interstitial, Echocardiography, Therapeutics, Hypertension, Pulmonary
Cited by
- [Diagnosis and Treatment of Pulmonary Embolism and Pulmonary Hypertension in Patients With Interstitial Lung Disease]. Open Respir Arch, 2025
- Shining a spotlight on pulmonary hypertension associated with interstitial lung disease care: The latest advances in diagnosis and treatment. J Manag Care Spec Pharm, 2025